SEC Form 4 · accession 0001127602-18-013111
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairman & CEO · Director
Period of report
Mar 28, 2018
Accepted (ET)
Mar 30, 2018 · 2:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 28, 2018 | M | 21,512 | $52.65 | A | 21,652 | D | |
| Common StockF2 | Mar 28, 2018 | S | 20,412 | $110.417 | D | 1,240 | D | |
| Common StockF3 | Mar 28, 2018 | S | 1,100 | $111.1827 | D | 140 | D | |
| Common Stock | Mar 29, 2018 | M | 21,512 | $52.65 | A | 21,652 | D | |
| Common StockF4 | Mar 29, 2018 | S | 2,790 | $110.4074 | D | 18,862 | D | |
| Common StockF5 | Mar 29, 2018 | S | 9,210 | $111.7827 | D | 9,652 | D | |
| Common StockF6 | Mar 29, 2018 | S | 9,512 | $112.2921 | D | 140 | D | |
| Common Stock | holding | — | — | — | 683,489 | I | By Trusts |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options | $52.65 | Mar 28, 2018 | M | 21,512 | D | Dec 31, 2009 | Dec 31, 2019 | Common Stock | 21,512 | 277,758 | D |
| Stock Options | $52.65 | Mar 29, 2018 | M | 21,512 | D | Dec 31, 2009 | Dec 31, 2019 | Common Stock | 21,512 | 256,246 | D |
Explanation of responses
- F1This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
- F2This transaction was executed in multiple trades at prices ranging from $110.00 to $110.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $111.00 to $111.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $110.00 to $110.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $111.05 to $112.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $112.06 to $112.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.